BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ 2017;20:740-8. [PMID: 28489467 DOI: 10.1080/13696998.2017.1325744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Keltanen TN, Heikman PK, Muhonen LH, Gunnar TO, Ojanperä IA. Enzymatic assay for urine lactose in the assessment of recent intravenous abuse of buprenorphine. Drug Test Anal 2019;11:1412-8. [DOI: 10.1002/dta.2654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Wright N, Hard J, Fearns C, Gilman M, Littlewood R, Clegg R, Parimelalagan L, Alam F. OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. Clinicoecon Outcomes Res 2020;12:499-504. [PMID: 32982339 DOI: 10.2147/CEOR.S256714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Martin E, Maher H, Mckeon G, Patterson S, Blake J, Chen KY. Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health. Journal of Substance Abuse Treatment 2022. [DOI: 10.1016/j.jsat.2022.108776] [Reference Citation Analysis]
4 Hsu YJ, Marsteller JA, Kachur SG, Fingerhood MI. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost. Popul Health Manag 2019;22:292-9. [PMID: 30543495 DOI: 10.1089/pop.2018.0163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
5 Zahra E, Chen R, Nielsen S, Tran AD, Santo T Jr, Degenhardt L, Farrell M, Byrne J, Ali R, Larance B. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. Drug Alcohol Rev 2022. [PMID: 35130368 DOI: 10.1111/dar.13437] [Reference Citation Analysis]
6 Phillips-Jackson H, Hallam C, Cullen N, Pearson T, Gilman M, Li L, Musgrave P. Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements. Clinicoecon Outcomes Res 2020;12:233-40. [PMID: 32440173 DOI: 10.2147/CEOR.S242984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Stone J, Fraser H, Young AM, Havens JR, Vickerman P. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. Int J Drug Policy 2021;88:102707. [PMID: 32151496 DOI: 10.1016/j.drugpo.2020.102707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]